KDR and colorectal cancer: In addition, EGCG (0.5–10 μM) has been shown to disrupt VEGFA-induced VEGFR2 dimerization in human umbilical vein endothelial cells [92], and inhibited growth and activation of VEGF/VEGFR axis in human colorectal cancer cells [93].